Evidence map›Paper›PMID 38580715›Full record

ArticleScientific reports2024

Targeted phasing of 2-200 kilobase DNA fragments with a short-read sequencer and a single-tube linked-read library method.

Veronika Mikhaylova, Madison Rzepka, Tetsuya Kawamura, Yu Xia, Peter L Chang, Shiguo Zhou, Amber Paasch, Long Pham, Naisarg Modi, Likun Yao and 7 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Veronika Mikhaylova *Universal Sequencing Technology Corp., Carlsbad, CA, 92011, USA.
Madison Rzepka *Universal Sequencing Technology Corp., Carlsbad, CA, 92011, USA.
Tetsuya Kawamura *Universal Sequencing Technology Corp., Carlsbad, CA, 92011, USA.
Yu Xia *Universal Sequencing Technology Corp., Carlsbad, CA, 92011, USA.
Peter L ChangUniversal Sequencing Technology Corp., Carlsbad, CA, 92011, USA.
Shiguo ZhouSage Science Inc., Beverly, MA, 01915, USA.
Amber PaaschUniversal Sequencing Technology Corp., Carlsbad, CA, 92011, USA.
Long PhamUniversal Sequencing Technology Corp., Carlsbad, CA, 92011, USA.
Naisarg ModiUniversal Sequencing Technology Corp., Carlsbad, CA, 92011, USA.
Likun YaoDepartment of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
Adrian Perez-AgustinDepartment of Medical Sciences, School of Medicine, University of Girona, Girona, Spain.
Sara PagansDepartment of Medical Sciences, School of Medicine, University of Girona, Girona, Spain.
T Christian BolesSage Science Inc., Beverly, MA, 01915, USA.
Ming LeiUniversal Sequencing Technology Corp., Canton, MA, 02021, USA.
Yong WangUniversal Sequencing Technology Corp., Canton, MA, 02021, USA.
Ivan Garcia-BassetsUniversal Sequencing Technology Corp., Carlsbad, CA, 92011, USA. ibassets@universalsequencing.com.
Zhoutao ChenUniversal Sequencing Technology Corp., Carlsbad, CA, 92011, USA. tchen@universalsequencing.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the human genome, heterozygous sites refer to genomic positions with a different allele or nucleotide variant on the maternal and paternal chromosomes. Resolving these allelic differences by chromosomal copy, also known as phasing, is achievable on a short-read sequencer when using a library preparation method that captures long-range genomic information. TELL-Seq is a library preparation that captures long-range genomic information with the aid of molecular identifiers (barcodes). The same barcode is used to tag the reads derived from the same long DNA fragment within a range of up to 200 kilobases (kb), generating linked-reads. This strategy can be used to phase an entire genome. Here, we introduce a TELL-Seq protocol developed for targeted applications, enabling the phasing of enriched loci of varying sizes, purity levels, and heterozygosity. To validate this protocol, we phased 2-200 kb loci enriched with different methods: CRISPR/Cas9-mediated excision coupled with pulse-field electrophoresis for the longest fragments, CRISPR/Cas9-mediated protection from exonuclease digestion for mid-size fragments, and long PCR for the shortest fragments. All selected loci have known clinical relevance: BRCA1, BRCA2, MLH1, MSH2, MSH6, APC, PMS2, SCN5A-SCN10A, and PKI3CA. Collectively, the analyses show that TELL-Seq can accurately phase 2-200 kb targets using a short-read sequencer.

Indexed as

GenomicsHigh-Throughput Nucleotide SequencingDNAGenome, HumanHumansSequence Analysis, DNADNA

Identifiers

PMID38580715
PMCPMC10997766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.